Imricor
Imricor, founded in 2006, specializes in developing MRI-compatible technology for cardiac procedures, including the Vision-MR Ablation Catheter and the Advantage-MR EP Recorder/Stimulator.
Company History
Imricor was founded in 2006 and has been a pioneer in MRI-compatible medical technology. In 2009, the company developed technology that allowed for MRI compatibility, marking a significant advancement in the field. The company achieved several milestones, including the first in-man diagnostic and ablation procedures in 2011 and the first human pilot study with Active MR Tracking in 2014. Imricor enrolled patients in a clinical trial in 2016 to support CE Mark approval for its Vision-MR Ablation Catheter. By 2020, the Vision-MR Ablation Catheter and Dispersive Electrode received CE Mark approval, and Imricor performed its first commercial procedure the same year.
Products
Imricor offers two key products: the Vision-MR Ablation Catheter and the Advantage-MR EP Recorder/Stimulator. The Vision-MR Ablation Catheter is the first and only iCMR ablation catheter designed to be used while a patient is being actively scanned in the iCMR. This catheter allows physicians to tailor treatments using real-time MRI. The Advantage-MR EP Recorder/Stimulator is an electrophysiology amplifier and recording system with an integrated cardiac stimulator, providing functionality for both recording intracardiac electrograms and pacing within the iCMR environment. The Vision-MR Dispersive Electrode minimizes eddy currents on conductive pads during MR scanning.
Key Milestones and Achievements
Imricor has achieved several significant milestones over its history. In 2011, the company performed its first in-man diagnostic and ablation procedures. This was followed by a successful human pilot study with Active MR Tracking in 2014. In 2016, Imricor received CE Mark approval for the Advantage-MR EP Recorder/Stimulator. The Vision-MR Ablation Catheter and Dispersive Electrode also received CE Mark approval in 2020. In 2021, the Advantage-MR received TGA approval, and the company established its first iCMR site in Switzerland in 2023. Key agreements, such as those with GE HealthCare, Philips, and various international distributors, have expanded the company's global footprint.
Global Partnerships and Agreements
Imricor has signed several strategic partnerships and agreements to expand its reach and capabilities. In 2018, the company signed its first customer contract with Dresden Heart Centre. A sales agreement with Philips was signed in 2020, and a distribution agreement with Regional Health Care Group followed in 2021, expanding Imricor's reach to Australia and New Zealand. Additionally, Imricor signed a memorandum of understanding with GE Healthcare in 2023 and a landmark agreement with a leading distributor in Saudi Arabia the same year. The company has also expanded its footprint to Qatar and signed a joint development agreement with ADIS for AI modules in NorthStar in 2023.